Oocyte maturation and fertilization initiates a dynamic and tightly regulated process in which a non-dividing oocyte is transformed into a rapidly dividing embryo. We have shown previously that two C. elegans CCCH zinc finger proteins, OMA-1 and OMA-2, have an essential and redundant function in oocyte maturation. Both OMA-1 and OMA-2 are expressed only in oocytes and 1-cell embryos, and need to be degraded rapidly after the first mitotic division for embryogenesis to proceed normally. We report here a distinct redundant function for OMA-1 and OMA-2 in the 1-cell embryo. Depletion of both oma-1 and oma-2 in embryos leads to embryonic lethality. We also show that OMA-1 protein is directly phosphorylated at T 239 by the DYRK kinase MBK-2, and that phosphorylation at T 239 is required both for OMA-1 function in the 1-cell embryo and its degradation after the first mitosis. OMA-1 phosphorylated at T 239 is only detected within a short developmental window of 1-cell embryos, beginning soon after the proposed activation of MBK-2. Phosphorylation at T 239 facilitates subsequent phosphorylation of OMA-1 by another kinase, GSK-3, at T 339 in vitro. Phosphorylation at both T 239 and T 339 are essential for correctly-timed OMA-1 degradation in vivo. We propose that a series of precisely-timed phosphorylation events regulates both the activity and the timing of degradation for OMA proteins, thereby allowing restricted and distinct functions of OMA-1 and OMA-2 in the maturing oocyte and 1-cell embryo, ensuring a normal oocyte-to-embryo transition in C. elegans. D
Introduction
In vertebrates, upon stimulation oocytes undergo maturation and are then arrested in meiotic metaphase II (Masui and Markert, 1971) . Fertilization activates meiosis II-arrested eggs to reenter the cell cycle and initiate embryonic development (review by Runft et al., 2002) . Egg activation is triggered by a rapid rise in cytosolic Ca ++ concentration, which has been shown in many systems to be both necessary and sufficient for the fertilized egg to reenter the cell cycle (reviews by BenYosef and Shalgi, 1998; Carroll, 2001; Runft et al., 2002) . The ability to release Ca ++ in response to fertilization changes during oogenesis, and reaches a maximum late during oocyte maturation (review by Carroll et al., 1996) . These observations suggest that successful activation at fertilization relies on changes occurring during oocyte maturation and that a precisely regulated transition from oocyte to embryo helps to ensure proper embryonic development. In addition to a rise in Ca ++ level, an equally important event during this transition is the turnover or inactivation of oocyte-and egg-specific proteins (DeRenzo and Seydoux, 2004) . However, little is known about inactivation of oocyte or egg specific proteins or the molecular mechanisms coordinating these events with the initiation of embryonic development.
C. elegans reproduces primarily as a self-fertilizing hermaphrodite. In a young adult, oocytes mature every 23 min and are normally immediately fertilized by sperm stores (see Fig. 1 ) (Detwiler et al., 2001; McCarter et al., 1999; Miller et al., 2001) . Fertilization triggers the completion of the two rounds of meiosis generating the oocyte pronucleus and extrusion of the two polar bodies (McCarter et al., 1999; McNally and McNally, 2005; Ward and Carrel, 1979) . In C. elegans, there is no obvious arrest between either oocyte maturation and fertilization or meiosis I and meiosis II (McCarter et al., 1999) , and therefore a stage equivalent to the egg of other systems does not exist. However, changes characteristic of egg activation, including an increase in cytosolic Ca ++ levels and completion of meioses, do occur upon fertilization (McCarter et al., 1999; McNally and McNally, 2005; Samuel et al., 2001) . Upon completion of the meiotic divisions, the oocyte pronucleus decondenses, migrates toward the now decondensed sperm pronucleus, and fuses with it. After the two pronuclei fuse, the zygote then enters metaphase of the first mitotic division without a preceding interphase (Fig. 1) . Centrosomes contributed by the sperm form the microtubuleorganizing center that cues the embryonic anterior -posterior polarity (Cowan and Hyman, 2004; Wallenfang and Seydoux, 2000) . In this article, the term oocyte-to-embryo transition will refer to the progression from initiation of oocyte maturation, through fertilization and activation, to telophase of the first mitotic division. We will use the term ''1-cell embryo'' to refer to embryos from immediately after fertilization to the completion of the first mitotic division.
Complex regulation of the oocyte-to-embryo transition is suggested by the dependence of one event upon successful completion of a previous event. For example, completion of oocyte maturation is required for fertilization to occur (Detwiler et al., 2001 ), which in turn is required for the completion of meiosis by the oocyte nucleus (McNally and McNally, 2005; Ward and Carrel, 1979) . Likewise, formation of sperm asters, the cue for embryonic polarity, depends upon successful completion of oocyte meiosis (Wallenfang and Seydoux, 2000) . The fact that C. elegans fertilization and embryonic development occur immediately following oocyte maturation also suggests that molecular events regulating the oocyte-to-embryo transition must be very precisely timed. While it remains unclear exactly how these events are coordinated, regulated protein degradation appears to play a key role (DeRenzo and Seydoux, 2004; Pellettieri et al., 2003) . First, formation of the mitotic spindle is dependent on the degradation of two meiotic microtubulesevering proteins, MEI-1 and MEI-2, whose functions are required for the meiotic spindle (Mains et al., 1990; Srayko et al., 2000) . Second, normal embryonic development requires the rapid degradation of OMA-1 and OMA-2 after the first mitotic division (Lin, 2003) . OMA-1 and OMA-2, two closely related CCCH zinc finger proteins that function redundantly in oocyte maturation, are expressed only in oocytes and the 1-cell embryo and are rapidly degraded soon after the first mitotic division (Detwiler et al., 2001; Lin, 2003) . Their correctly timed degradation is essential for proper embryonic development, as an oma-1 gain-of-function mutation (zu405) that leads to OMA-1 persistence results in embryonic lethality (Lin, 2003) . Third, the asymmetric segregation of PIE-1, MEX-1 and POS-1, three other CCCH zinc finger proteins specific to the germ cell precursors (Guedes and Priess, 1997; Mello et al., 1996; Reese et al., 2000; Tabara et al., 1999) , is, in part, regulated by the degradation of these proteins in non-germ cell precursors (Reese et al., 2000) .
MEI-1/2, OMA-1/2, PIE-1, and POS-1 have very different spatiotemporal expression and degradation patterns, and yet all require the DYRK kinase family member MBK-2 for their regulated degradation (Pang et al., 2004; Pellettieri et al., 2003; Quintin et al., 2003) . Depletion of mbk-2 either genetically or by RNAi results in pleiotropic defects in the early embryo, including defects in the degradation of these proteins (Pang et al., 2004; Pellettieri et al., 2003; Quintin et al., 2003) . DYRK kinases have been implicated in a number of important biological processes, including neuronal function (Fotaki et al., 2002; Raich et al., 2003; Tejedor et al., 1995) , Down syndrome (Altafaj et al., 2001; Smith and Rubin, 1997; and cancer (Lee et al., 2000; Miller et al., 2003) . However, our understanding of cellular functions of DYRK kinases remains limited due to the lack of identified in vivo substrates.
Since a number of processes in the oocyte-to-embryo transition depend on mbk-2, it has been suggested as a key regulator of the transition (Pellettieri et al., 2003) . However, how MBK-2 regulates this transition at a molecular level is unclear because no in vivo substrate has yet been identified. MBK-2 might regulate a number of diverse cellular processes directly via phosphorylation of distinct substrates. Alternatively, MBK-2 might phosphorylate a single substrate that then regulates a number of different downstream processes. The subcellular localization of GFP::MBK-2 undergoes a dramatic rearrangement in embryos prior to meiosis II, changing from a uniform to Fig. 1 . Schematic diagram of a wildtype C. elegans hermaphrodite gonad, oocytes, and the first mitotic cycle. Germ nuclei (white circles) are in a syncitial cytoplasm of the gonad arm before being enclosed by membranes to form developing oocytes. The oocyte adjacent to the spermatheca (maturing oocyte) undergoes maturation, and is then immediately ovulated and fertilized. Small black ovals: polar bodies (anterior end of embryo).
a punctate pattern at the cortex (Pellettieri et al., 2003) . It has been proposed that this change in subcellular localization coincides with MBK-2 activation (Pellettieri et al., 2003) . However, while the degradation of MEI-1 occurs soon after the proposed activation of MBK-2 (Clark-Maguire and Mains, 1994; Pintard et al., 2003) , the degradation of OMA-1 and PIE-1 does not occur until first mitotic anaphase and the 2-cell stage, respectively (Lin, 2003; Reese et al., 2000) . How this temporal difference in degradation kinetics is achieved is also unclear.
Here, we identify OMA-1 as an in vivo substrate for MBK-2. We show that OMA-1 degradation requires direct phosphorylation by MBK-2 at T 239 , and that this phosphorylation is diminished in the oma-1(zu405) gain-of-function mutant embryo, resulting in OMA-1 persistence. OMA-1 is phosphorylated at T 239 only within the short developmental window following completion of meiosis II until OMA-1 is normally degraded. We also show that OMA-1 is phosphorylated by another kinase, GSK-3, at T 339 in vitro and that this phosphorylation is also crucial for OMA-1 degradation in vivo. Sequential phosphorylation is suggested by the observation that phosphorylation of T 339 by GSK-3 in vitro is facilitated by amino acid substitutions that mimic phosphorylated T 239 . Finally, we show that OMA-1 and OMA-2 have a redundant function in 1-cell embryos that is required for embryonic development and that this function is distinct from their role in oocyte maturation. We propose a model whereby sequential phosphorylation by MBK-2 and GSK-3 converts OMA-1 and OMA-2 from being key regulators of oocyte maturation to key regulators of 1-cell embryo development, as well as ensuring their timely degradation after the first mitotic cycle.
Materials and methods

Strains
N2 was used as the wildtype strain. Genetic markers are: LGII, rrf-3(pk1426); LGIII, unc-119(ed3), ruIs32[unc-119(+) P pie-1 ::GFP::H2B]; LGIV, oma-1(te21), oma-1(te33), oma-1(zu405), mbk-2(pk1427); LGV, oma-2(te50), oma-2(te51), nT1(IV;V). Transgenic strains were generated by microparticle bombardment (Praitis et al., 2001) . teIs20 (P oma-1 DNoma-1::gfp); teIs21 (P oma-1 DNoma-1 T239A ::gfp); teIs23 (P oma-1 DNoma-1 T239A S302A ::gfp); teIs22 (P oma-1 DNoma-1 S302A ::gfp); teIs61 (P oma-1 DNoma-1 T339A ::gfp). The expression patterns of each transgene were verified in at least three independent lines.
Plasmid construction
All expression clones were generated using the Gateway technology (Invitrogen). The P oma-1 gfp destination vector pRL781 contains 2.1 kb upstream, and 1 kb downstream of OMA-1 coding sequence. Desired oma-1 cDNA fragments were recombined into pRL781, generating OMA-1 protein with GFP at the C-terminus. pMALp2X-and pcDNA3.1-derived vectors were used for N-terminally tagged MBP and FLAG, respectively, fusion proteins. The gsk-3 RNAi feeding vector was derived from pDONRdT7 (Reddien et al., 2005) . All site-directed mutagenesis was performed using the Quick Change kit (Stratagene). The kinase dead mutations used were Y 237 A for MBK-2 and Y 196 F for GSK-3.
In vitro kinase assays
All substrates and kinases except GSK-3 used in this study were MBPtagged. MBP fusions were produced in Rosetta (DE3) pLysS (Novagen) cells.
Cells were sonicated in (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, Complete protease inhibitor [Roche]), treated with 0.1 U/Al DNase and 0.01 Ag/Al RNaseA, and fusion protein purified by amylose resin (NEB). All substrates were eluted with 10-mM maltose, whereas resin-bound MBK-2 kinases were used directly for kinase assay. 1% TritonX-100 was added to solubilize MBK-2 during purification.
Sixty hours after transfection, HEK293T cells were lysed (10 mM NaPO 4 pH 7.2, 150 mM NaCl, 1% NP40, 1 mM EDTA, Complete protease inhibitor [Roche] , phosphatase inhibitor cocktail I [Calbiochem], 1 mM NaVO 4 ), and FLAG::GSK-3 was immunoprecipitated using protein G beads (Pierce) and anti-FLAG M2 antibody, and eluted with 1 mM FLAG peptide (Sigma). Recombinant Rabbit GSK-3h was purchased from New England Biolabs.
MBK-2 (25 mM HEPES pH 7.6, 5 mM MgCl 2 , 5 mM MnCl 2 , 0.5 mM DTT, 30 nM cold ATP and 0.5 ACi [g- 
Antibody production and immunofluorescence
Anti-T 239 -P antibody was generated by immunizing rabbits with the peptide RLPEP4 HPLEMFARPST(PO 4 )PDEPAAK in which threonine 239 is phosphorylated. The antibodies were precleared with the non-phosphorylated peptide counterpart before being affinity-purified using the phosphorylated peptide (Bethyl Laboratory, Inc). In ELISA assays, the affinity-purified anti-T 239 -P antibody reacts with phosphorylated RLPEP4 with at least 100-fold higher affinity compared to the unphosphorylated RLPEP4 or unrelated peptides. This affinity-purified antibody fails to detect any protein in worm extracts or recombinant OMA-1 phosphorylated by MBK-2 as assayed by western blots.
Immunofluorescence of embryos using anti-T 239 -P was performed as described (Lin et al., 1998) 
Analysis of embryos and imaging
Imaging of immunofluorescence and live embryos was performed as described previously (Rogers et al., 2002) . The filter wheels (Ludl Electronic Product) and shutter controller are driven by a custom software package (os4d 1.0, freely available upon request to jwaddle@mail.smu.edu).
RNAi screen for genes required for OMA-1 degradation
Feeding RNAi for oma-2 and gsk-3 were performed at 25-C by placing L2 worms onto RNAi bacteria and scoring 24 -30 h later (Detwiler et al., 2001; Timmons and Fire, 1998) .
RNAi clones from the Ahringer RNAi feeding library that gave rise to either sterile or embryonic lethal progeny (Fraser et al., 2000; Kamath et al., 2003; Simmer et al., 2003) , or that were enriched in the germline (Reinke et al., 2000) were selected to conduct the screen using TX492 [teIs1 ( P oma-1 oma-1::gfp); rrf-3(pk1426)] (Simmer et al., 2002; Lin, 2003) . TX492 L1 were placed on RNAi plates for 3 days at 20-C before scoring. Any clone resulted in an OMA-1::GFP pattern deviated from the wild-type pattern was retested.
Results
MBK-2 phosphorylates OMA-1 in vitro, primarily at T 239
To investigate whether MBK-2 has a direct role in OMA-1 degradation, we began by determining whether MBK-2 can phosphorylate OMA-1 in vitro. It has been shown, in vitro, that mammalian DYRK1 and DYRK2 prefer to phosphorylate a serine or threonine with the following consensus sequence: RXXS/TP (Campbell and Proud, 2002; Himpel et al., 2000) . The arginine at the À3 position is essential, whereas the proline at the +1 position is highly favored (Campbell and Proud, 2002; Himpel et al., 2000) . Replacing the P at the +1 position with the hydrophobic amino acid valine still permits phosphorylation by DYRK2 in vitro, although the K m is increased more than 10-fold (Campbell and Proud, 2002) . Examination of the OMA-1 and OMA-2 sequences revealed two such DYRK consensus sites in each protein (T 239 and S 302 for OMA-1; T 227 and S 291 for OMA-2, Fig. 2A ).
We tested whether MBK-2 can directly phosphorylate OMA-1 or OMA-2 in vitro and, if so, whether it does so via these putative substrate sites. Using bacterially expressed kinase and substrates, we found that wild-type, but not kinase-dead, MBK-2 phosphorylates both OMA-1 and OMA-2 in vitro (Fig. 2B) . In a parallel reaction, MBK-2 did not phosphorylate C. elegans cyclin B (Fig. 2B) , a protein that, like OMA-1, is rapidly degraded in the 1-cell embryo but whose degradation is known to be independent of MBK-2 (Pellettieri et al., 2003) .
To investigate whether MBK-2 phosphorylates OMA-1 at specific sites, we performed kinase assays using OMA-1 proteins in which T 239 , S 302 , or both, had been mutated to alanine (Fig. 2B) . While changing S 302 to alanine resulted in only a minor decrease in the overall phosphorylation of OMA-1, changing T 239 to alanine abolished most of the phosphorylation signal. OMA-1 with both T 239 A and S 302 A substitutions had a level of phosphorylation very close to background. This result suggests that, in vitro, MBK-2 phosphorylates OMA-1 primarily at T 239 but can also phosphorylate S 302 . In addition, it appears that these two sites account for the vast bulk of OMA-1 phosphorylation by MBK-2.
The oma-1 gain-of-function mutation, zu405, which results in prolonged persistence of OMA-1 protein past the 1-cell stage, changes the proline at the +1 position of the T 239 consensus site to a leucine (Lin, 2003) . As the change of proline at the +1 position to valine was shown to increase the K m dramatically for the DYRK2 kinase (Campbell and Proud, 2002) , the zu405 mutation would be predicted to also affect phosphorylation of OMA-1 by the MBK-2 kinase. We directly tested this prediction using the in vitro kinase assay (Fig. 2C) . OMA-1 with P 240 L and P 240 L S 302 A changes resulted in reductions in OMA-1 phosphorylation similar to those observed with T 239 A and T 239 A S 302 A changes, respectively. This result suggests that P 240 is important for phosphorylation of OMA-1 at T 239 by MBK-2 in vitro and that MBK-2 might therefore have a direct role in vivo in regulating OMA-1 degradation.
Phosphorylation of OMA-1 at T 239 is detected in embryos after MBK-2 activation and before OMA-1 degradation
To determine whether OMA-1 phosphorylation at T 239 occurs in vivo, we raised antibodies that specifically recognize this epitope (anti-T 239 -P). We performed immunofluorescence with the anti-T 239 -P antibody to investigate the in vivo spatiotemporal distribution of T 239 -phosphorylated OMA-1. While OMA-1 (and OMA-2) is expressed at a high level in oocytes, no signal was detected in oocytes or any part of the gonad with the anti-T 239 -P antibody (data not shown). We did, however, detect a high cytoplasmic signal in a specific subset of 1-cell embryos (Fig. 3A) , with no signal detected in embryos past the 1-cell stage. Precise staging of the embryos showed that the staining was detected only after meiosis II and before anaphase of the first mitotic division (0/9 at meiosis I, 0/4 at meiosis II, 25/25 after meiosis II to first mitotic metaphase, 0/2 at first mitotic anaphase, 0/11 at 2-cell stage). This time window corresponds to the period soon after the proposed activation of MBK-2 (Pellettieri et al., 2003) until endogenous OMA-1 degradation (Lin, 2003) . This observation is the first molecular evidence correlating MBK-2 redistribution with its activation. These data also support the proposal that phosphorylation of OMA-1 at T 239 is carried out by MBK-2 in vivo.
Phosphorylation of OMA-1 at T 239 depends on MBK-2
The onset of T 239 phosphorylation in 1-cell embryos follows the proposed activation of MBK-2 (Pellettieri et al., 2003) . We then asked whether the phosphorylation of OMA-1 at T 239 in vivo is dependent on the MBK-2 kinase by staining embryos derived from homozygous mbk-2(pk1427) worms (Raich et al., 2003) . One hundred percent of these embryos have early cleavage defects, and appear as 1-cell or multicellular embryos due to a defect in cytokinesis (Pellettieri et al., 2003) . These embryos exhibit high OMA-1 protein levels, as shown previously (Pellettieri et al., 2003) and confirmed here (data not shown). Strikingly, none of the mbk-2(pk1427) embryos examined (n > 500) exhibited detectable anti-T 239 -P staining (Fig. 3B) . Meanwhile, every one of these mbk-2(pk1427) embryos was correctly co-stained with the control PIE-1 antibody (Fig. 3B) (Pellettieri et al., 2003) . Taken together, the in vitro phosphorylation of OMA-1 by MBK-2, the close timing of proposed MBK-2 activation and T 239 phosphorylation, and the dependence of phosphorylation at T 239 on MBK-2 all strongly suggest that MBK-2 phosphorylates OMA-1 at T 239 in vivo, thereby promoting OMA-1 degradation.
MBK-2-dependent phosphorylation of OMA-1 is not detected in oma-1(zu405) embryos
The oma-1(zu405) P 240 L mutation diminished the in vitro phosphorylation at T 239 by MBK-2 (Fig. 2C) . To further investigate a direct role in vivo for MBK-2 in phosphorylation of OMA-1 at T 239 , we examined T 239 phosphorylation in oma-1(zu405) embryos by immunofluorescence. Interpretation of antibody-staining results is complicated by the fact that sequences surrounding T 227 in OMA-2 and T 239 in OMA-1 are nearly identical ( Fig. 2A) , making it likely that anti-T 239 -P recognizes phosphorylated epitopes in both OMA-1 and OMA-2. Consistent with anti-T 239 -P antibody recognizing both OMA-1 and OMA-2, the 1-cell staining was still detected in either oma-1(te33) or oma-2(te51) null mutant embryos (data not shown). In an attempt to eliminate antibody staining deriving from OMA-2, we performed antibody staining in oma-1(zu405) embryos depleted of oma-2 by RNAi. We have shown previously that oma-2(RNAi) depletes OMA-2 protein while leaving OMA-1 levels unaffected (Detwiler et al., 2001) . In 1-cell oma-1(zu405);oma-2(RNAi) embryos (n > 70), no anti-T 239 -P staining was detected (Fig. 3B ). This result demonstrates the specificity of this anti-T 239 -P antibody for OMA-1 and OMA-2 proteins in the 1-cell embryo. Although we are unable to completely exclude the possibility that the Pto-L change interferes with the epitope recognition of T 239 -P by the anti-T 239 -P antibody, the absence of detectable antibody staining, along with the in vitro phosphorylation result, strongly suggests that the zu405 mutation diminishes phosphorylation at T 239 .
GSK-3 kinase is also required for OMA-1 degradation in vivo
In the course of an RNAi screen using an OMA-1::GFP strain as a reporter aimed at identifying other genes regulating OMA-1 degradation, we discovered that the C. elegans gsk-3 homolog is required for OMA-1 degradation. Depletion of gsk-3 by RNAi results in a severe delay in the degradation of OMA-1 protein, similar to that observed in mbk-2(RNAi) embryos (Fig. 4A) . However, unlike mbk-2(RNAi) or mbk-2(pk1427) embryos, gsk-3(RNAi) embryos do not have gross defects in early embryonic divisions (Schlesinger et al., 1999) .
GSK-3 phosphorylation of OMA-1 in vitro is affected by the phosphorylation state at T 239
To investigate whether GSK-3, like MBK-2, plays a direct role in OMA-1/OMA-2 degradation, we first asked whether GSK-3 can phosphorylate OMA-1 or OMA-2 in vitro. Phosphorylation of many proteins by GSK-3 first requires that a serine or threonine four residues C-terminal be phosphorylated by a priming kinase (Biondi and Nebreda, 2003; Fiol et al., 1987) . GSK-3 dependent phosphorylation of an initial S/T target can then prime additional GSK-3 dependent phosphor- ylation of S/T located 4 residues N-terminal. Although preferred substrate sequences for C. elegans GSK-3 have not been characterized, they are likely to be similar to those found for vertebrate GSK-3 kinases, given the high sequence similarity between these proteins (Schlesinger et al., 1999) . Examination of OMA-1 and OMA-2 sequences identifies several potential GSK-3 phosphorylation sites (Fig. 4B ): S 331 , S 335 , and T 339 for OMA-1, and S 319 , S 323 , and T 327 for OMA-2. Sequences surrounding these sites are nearly identical between OMA-1 and OMA-2, and the residues at the +4 position relative to T 339 in OMA-1 and T 327 in OMA-2 are aspartate (D), an amino acid known to be able to mimic phosphorylated serine or threonine residues. D 343 and D 331 could therefore prime GSK-3 phosphorylation of T 339 in OMA-1 and T 327 in OMA-2, respectively.
Using recombinant GSK-3 kinase, both OMA-1 and OMA-2 can be phosphorylated in vitro (Fig. 4C and data not shown) . OMA-1 can be phosphorylated with similar specificity with either bacterially-expressed rabbit GSK-3 or worm GSK-3 isolated from transfected HEK293T cells (data not shown). Mutating the most C-terminal candidate GSK-3 phosphorylation sites (T 339 of OMA-1 and T 327 of OMA-2) to alanines reduced but did not abolish phosphorylation by GSK-3 in vitro (Fig. 4C) . This was not due to phosphorylation of nearby sites because OMA-1 with seven additional mutations that changed all threonine and serine residues surrounding T 339 (from S 331 to S 347 ) to alanines was still phosphorylated to a similar extent as OMA-1 T 339 A (data not shown). However, mutating T 239 , in addition to T 339 , to alanine abolished most, if not all, phosphorylation by GSK-3 in our assay (Fig. 4C) . In fact, mutation of T 239 to alanine alone diminished OMA-1 phosphorylation by GSK-3 to a near background level. Conversely, when T 239 was mutated to aspartate or glutamate, phosphorylation of OMA-1 by GSK-3 was reduced only slightly (Fig. 4C) . We conclude from the kinase assay that phosphorylation at T 239 appears to facilitate in vitro phosphorylation at T 339 by GSK-3. This is contrary to the in vitro phosphorylation of T 239 by MBK-2, which is unaffected by whether position 339 is a threonine, alanine, or aspartate (data not shown). It is interesting to note that, although only T 339 , and not T 239 , is a predicted GSK-3 substrate site, it would appear that both sites can be phosphorylated by GSK-3 in vitro.
We did not, however, detect a significant difference in anti-T 239 -P signal between gsk-3(RNAi) and non-RNAi embryos (Fig. 4D) , suggesting that GSK-3 does not phosphorylate T 239 in vivo in a significant way. This result, plus the observation that anti-T 239 -P staining is abolished in mbk-2 embryos, demonstrates that T 239 is phosphorylated in vivo primarily, if not exclusively, by MBK-2. Taken together, our results suggest that, in vivo, phosphorylation at T 239 by MBK-2 likely facilitates phosphorylation at T 339 by GSK-3.
Phosphorylation of OMA-1 at both T 239 and T 339 is essential for OMA-1 degradation in vivo
To evaluate functional importance of T 239 , S 302 and T 339 phosphorylation in OMA-1 degradation, we examined the stability of OMA-1 protein in which phosphorylation at one or more of these three sites is prevented. Failure to degrade OMA-1 protein (as in oma-1(zu405) embryos) results in embryonic lethality (Lin, 2003) , precluding the use of a functional protein for such analysis. Thus, all analyses were performed using a truncated OMA-1 protein in which the sequence N-terminal to the first zinc finger is deleted (OMA-1DN) . Expression of OMA-1DN::GFP in wildtype worms did not cause any lethality or abnormal phenotype (data not shown). In addition, OMA-1DN::GFP was degraded following the first mitotic division, albeit at a slightly slower rate compared to full-length OMA-1 (Fig. 5) . Importantly, OMA-1DN::GFP proteins with either T 239 or T 339 changed to alanine demonstrated a very severe defect in OMA-1 degradation (Fig. 5) , with OMA-1DN::GFP persisting in embryos as late as the 100-cell stage (data not shown). GFP was detected throughout the entire embryo with a higher abundance in germline precursors (Fig. 5) . Consistent with S 302 being a secondary site for MBK-2 in vitro, the S 302 A change resulted in only a minor defect in OMA-1 degradation and did not exacerbate the OMA-1T 239 A defect in vivo (Fig.  5) . These results are consistent with phosphorylation of both T 239 , by MBK-2, and T 339 , by GSK-3, being essential for correct timing of OMA-1 degradation in vivo.
OMA-1 and OMA-2 have a redundant role in embryogenesis
Cyclin B and MEI-1/2 are degraded soon after their functions in oocyte maturation and meiotic division, respectively (Clark-Maguire and Mains, 1994; Liu et al., 2004; Sonneville and Gonczy, 2004) In contrast, OMA-1 and OMA-2 persist until anaphase of the first mitotic division, approximately 1 h after completion of oocyte maturation (Lin, 2003) . This marked delay led us to investigate whether OMA-1 and OMA-2 have any function in one-cell embryos.
Animals homozygous for loss-of-function mutations in both oma-1 and oma-2 genes are sterile (Detwiler et al., 2001) , and therefore we could not directly address the potential function of OMA-1 or OMA-2 in the 1-cell embryo. However, two observations offer strong support for the notion that OMA-1 and OMA-2 have functions in the 1-cell embryo required for proper embryogenesis and that, as in oocyte maturation, these functions are redundant. First, worms homozygous for reduction-of-function oma-1(te21) and oma-2(te50) alleles (Detwiler et al., 2001) are not fully penetrant for the oocyte maturation defect and can produce embryos. However, they produce only dead embryos that have complex phenotypes, including fragile eggshells and severe cleavage defects (100%, n > 500). Using an H2B::GFP reporter, we observed polar bodies in most of these embryos, indicating that these embryos have been fertilized and have completed meiosis (Fig. 6) . Although the phenotypes of these dead embryos vary, the majority presented a dramatic difference in cell division defects between cells derived from the anterior versus posterior portions of the embryo. Cells in most of these mutant embryos are found in two distinct clumps: an anterior clump which appears to be derived from the anterior cell, AB, of the two-cell stage embryo, and a posterior clump derived from the two-cell stage posterior cell, P1 (Fig. 6) . In most cases, the anterior clump consists of several hundred cells, whereas the posterior clump remains as a large single cell with multiple disorganized nuclei.
Second, depletion of oma-2 by RNAi in the oma-1(zu405) background at a permissive temperature results in 100% dead embryos (n > 500). This is in contrast to the 50% lethality at the same temperature for embryos produced by oma-1(zu405) animals (n > 500). The oma-1(zu405);oma-2(RNAi) animals do not appear to have any defect in oocyte maturation (data not shown). The phenotype of arrested embryos resembles but is not identical to that of zu405 embryos (Lin, 2003) . While excess pharynx is evident in almost all oma-1(zu405);oma-2(RNAi) embryos, no excess intestinal cells were observed (data not shown). Further characterizations of this phenotype will be reported elsewhere. Because OMA-2 is only expressed in oocytes and the 1-cell embryo, the enhanced lethality of oma-1(zu405) embryos at a permissive temperature would appear to be a result of OMA-2 depletion in the 1-cell embryos. However, the requirement for OMA-2 in the 1-cell stage is only Fig. 6 . oma-1(te21);oma-2(te50) embryos have severe defects in early cleavage. DIC (left column) or GFP::H2B fluorescence (right column) micrographs of embryos derived from wildtype or oma-1(te21);oma-2(te50). Genotype for each embryo is shown to the left. AB and P1 blastomeres in the 2-cell stage wildtype embryo are indicated. Arrows point to polar bodies that mark the anterior end of the C. elegans embryo. Scale bar: 30 Am. revealed in the oma-1(zu405) genetic background, as no abnormal phenotype was observed in oma-1(+) embryos depleted of oma-2 either genetically or by RNAi (Detwiler et al., 2001) . Our interpretation from the above two observations is: (1) OMA-1 and OMA-2 have a redundant function in the 1-cell embryo distinct from their redundant function in oocyte maturation; and (2) while the mutant OMA-1 P 240 L protein can substitute for the wild-type OMA-1 protein in maturing oocytes, it cannot substitute for the wildtype OMA-1 function in 1-cell embryos.
Discussion
We report here that the transition from oocyte to embryo in C. elegans requires the functions of OMA-1 and OMA-2 in both the maturing oocyte and the 1-cell embryo. For embryonic development to proceed normally, the OMA-1 protein must be rapidly degraded immediately after the first mitotic metaphase (Lin, 2003) . We show that this precisely-timed degradation requires combined, and likely sequential, phosphorylation by MBK-2 and GSK-3 at two distinct sites on the OMA-1 protein, with GSK-3 phosphorylation facilitated by prior MBK-2 phosphorylation. Although no gain-of-function oma-2 mutation is available, we believe that OMA-2 degradation is subject to a similar regulation and is essential for embryogenesis based on the in vivo expression pattern of OMA-2, in vitro and in vivo phosphorylation by MBK-2, and the high degree of sequence similarity between OMA-1 and OMA-2.
Redundant function in the 1-cell embryo?
Our data strongly suggest that OMA-1 and OMA-2 have a redundant function in 1-cell embryos, and that their function in 1-cell embryos is distinct from their redundant function in oocyte maturation. Our result that oma-1(zu405);oma-2(RNAi) embryos produce 100% dead embryos with no apparent defects in oocyte maturation further suggests that OMA-1 P 240 L can substitute for wild-type OMA-1, but only in oocytes and not in embryos. We could not rule out the possibility that the embryonic defects observed in oma-1(te21);oma-2(te50) and oma-1(zu405);oma-2(RNAi) embryos were due to the reduced function of OMA-1 and OMA-2 in the oocyte, leading to imperfect maturation. However, we find it difficult to reconcile imperfect oocyte maturation with such different phenotypes in the two genetic backgrounds, as well as such different defects in the AB-versus P1-derived lineages in oma-1(te21);oma-2(te50) embryos.
The differential ability of OMA-1P 240 L to substitute for wild-type OMA-1 protein in oocyte maturation versus 1-cell embryos is very interesting. Because the P 240 L mutation prevents phosphorylation at T 239 by MBK-2 in vitro, and likely in vivo, this suggests that phosphorylation at T 239 is important for OMA-1 function in the 1-cell stage embryo. Consistent with our result that T 239 is not phosphorylated in oocytes, the P 240 L mutation does not inhibit OMA-1 function in oocytes. An intriguing, albeit highly speculative, possibility is that phosphorylation of OMA-1 at T 239 by MBK-2 is involved in switching OMA-1 from a regulator for oocyte maturation to a regulator for events in the 1-cell embryo, in addition to facilitating phosphorylation by GSK-3. The phenotype of oma-1(zu405);oma-2(RNAi) embryos argues that the zu405 mutation does not simply result in an excess of wildtype OMA-1 protein (Lin, 2003) . Rather, it is consistent with zu405 being a neomorphic allele that has a modified function different from the function of the wild-type allele.
Possible function for OMA proteins in embryos
The phenotype of oma-1(te21);oma-2(te50) embryos suggests that OMA protein function is required primarily for the proper development of the P1 cell. Many key regulators important for proper embryonic development in C. elegans are differentially localized between AB and P1 at the first embryonic division (Kemphues and Strome, 1997; Schnabel and Priess, 1997) . It is possible that the function of OMA-1 and OMA-2 in the 1-cell embryo leads to the restriction of a key developmental regulator to either P1 or AB. Depletion of OMA proteins could result in the absence of a P1 factor or the ectopic activity of an AB factor, respectively, in P1, and therefore, the P1 lineage defects. Although many P1-or AB-restricted factors have been characterized to date, depletion of any individually, or many in combination, did not result in a phenotype resembling that shown here for oma-1(te21);oma-2(te50), (Bowerman et al., 1992; Guedes and Priess, 1997; Kawasaki et al., 1998; Kuznicki et al., 2000; Mello et al., 1992; Tabara et al., 1999) . The molecular target(s) of OMA-1 and OMA-2 in the 1-cell embryo is currently being investigated.
Dual regulation of OMA-1 by MBK-2 and GSK-3
Although phosphorylation of OMA-1 at both T 239 and T 339 is essential for its correct temporal degradation in vivo, phosphorylation at each site might serve different purposes. We propose that a series of co-dependent events, including phosphorylation of OMA-1 and OMA-2, regulates their differential activities in both oocytes and 1-cell embryos, as well as the timing of their degradation (Fig. 7) . We propose that MBK-2 phosphorylation at T 239 serves three purposes: (1) it limits degradation of OMA proteins to only after completion of oocyte maturation. MBK-2 does not appear to be activated until just before meiosis II, which is supported by our results here. Therefore, OMA-1 phosphorylation at T 239 does not occur until after the OMA proteins have completed their functions in oocyte maturation. (2) As mentioned above, we propose that phosphorylation at T 239 switches OMA-1 from a regulator of oocyte maturation to a regulator of events in the 1-cell embryo. (3) It permits the subsequent phosphorylation of T 339 by GSK-3 and eventual OMA degradation. While phosphorylation of OMA-1 at T 239 occurs soon after meiosis II, OMA-1 is not degraded until approximately 40 min later, in contrast to the rapid degradation of another candidate substrate for MBK-2, MEI-1 (Clark-Maguire and Mains, 1994; Pintard et al., 2003) . We propose that additional levels of regulation, including phosphorylation by GSK-3, delay the degradation of OMA proteins such that they can complete their functions in the 1-cell embryo. In addition, it is possible that GSK-3 phosphorylation is also required for the OMA proteins to carry out their 1-cell embryo specific function.
In vertebrates, GSK-3 is inactivated by an inhibitory phosphorylation at its N-terminus (Ser 21 in GSK3a and Ser 9 in GSK3h) that binds to and inhibits the kinase domain by serving as a pseudosubstrate (Cross et al., 1995; Frame et al., 2001; Sutherland et al., 1993) . The sequence surrounding these inhibitory phosphorylation sites is not conserved in C. elegans GSK-3, and therefore it is not clear whether its activity is subjected to a similar regulation in vivo. It is possible that in C. elegans, GSK-3 is inactive in the 1-cell embryo until immediately before OMA-1 degradation. Alternatively, GSK-3 might be constitutively active in the C. elegans embryo, but the sequential phosphorylation by MBK-2 and GSK-3 is enough to delay the degradation of OMA-1 until the end of the first mitosis.
GSK-3 and protein degradation
Although we did not demonstrate that GSK-3 phosphorylates OMA-1 in vivo, our results strongly suggest that GSK-3 phosphorylates and promotes OMA-1 degradation in vivo. Phosphorylation by GSK-3 has been linked to the degradation of key regulators in both the Wnt and hedgehog signaling pathways, h-catenin (Aberle et al., 1997) and Ci (Jia et al., 2002; Price and Kalderon, 2002) , respectively. However, the precise mechanism by which phosphorylation of h-catenin and Ci triggers their degradation remains to be elucidated. Similarly, the mechanism by which phosphorylation at T 239 and T 339 promotes OMA-1 degradation is not known. Degradation of OMA-1 is proteasome dependent (Y.N. and R. L., unpublished results). It is possible that phosphorylation at T 339 (and/or T 239 ) creates a recognition motif for an E3 ubiquitin ligase to ubiquitinate OMA-1. Alternatively, phosphorylation at T 339 might facilitate additional phosphorylation events that affect OMA-1 degradation.
It is interesting to note that the phenotypes of embryos carrying the oma-1(zu405) mutation, in which OMA-1 degradation is drastically delayed, are very similar to that of embryos depleted of gsk-3 by RNAi (Lin, 2003; Maduro et al., 2001; Schlesinger et al., 1999) . Both strains have a non-penetrant defect in the Wnt signaling pathway that specifies the endoderm precursor, a fate transformation in the C blastomere allowing it to produce endoderm, and defects in the degradation of other maternal factors (Lin, 2003; Maduro et al., 2001; Schlesinger et al., 1999; Y.N. and R. L., unpublished results) . One intriguing possibility is that the primary role of GSK-3 in early C. elegans development is to degrade OMA-1 (and likely OMA-2) protein. This possibility is currently under investigation.
DYRK kinase and protein degradation
Depletion of mbk-2 affects the degradation of many maternal proteins (Pang et al., 2004; Pellettieri et al., 2003; Quintin et al., 2003) . Within this group, degradation of PIE-1 and POS-1 is also defective in the oma-1(zu405) mutant (Lin, 2003) . Because there are no obvious potential substrate sites for DYRK2 kinase (Campbell and Proud, 2002) in PIE-1 or POS-1, the observed degradation defect for these two proteins could be an indirect effect of OMA-1 persistence. However, the degradation of MEI-1 occurs prior to the degradation of OMA-1 in wildtype embryos (Clark-Maguire and Mains, 1994; Lin, 2003) and oma-1(zu405) embryos do not resemble the mei-1 gain-of-function phenotype. It is therefore unlikely that MBK-2 regulates MEI-1 degradation indirectly through OMA-1. The pleiotropic defects associated with the mbk-2 mutant and the complex subcellular localization of MBK-2 protein suggest that MBK-2 might directly regulate multiple proteins. It remains unclear why MBK-2 undergoes a dramatic change in subcellular location at the time of activation and how the cortically localized MBK-2 then phosphorylates substrates at diverse subcellular locations.
Human DYRK1B has been shown to phosphorylate and destabilize cyclin D1 in vivo (Zou et al., 2004) . As a nondegradable form of cyclin D1 is capable of transforming murine fibroblasts and promoting tumor growth in immune compromised mice, regulated degradation of cyclinD1 by DYRK1B phosphorylation is important for proper control of cell divisions (Alt et al., 2000) . We extend this observation by demonstrating that MBK-2 phosphorylation regulates the stability, and likely activity, of key players in the oocyte-to-embryo transition. Furthermore, we show that the degradation of OMA proteins requires a combined regulation by MBK-2 and GSK-3. Phosphorylation at T 239 might induce a conformational change in OMA-1 that makes T 339 accessible for GSK-3. In vitro, DYRK kinases have been shown to phosphorylate specific residues of several cytoplasmic proteins, priming for GSK-3 kinase-dependent phosphorylation (Chen-Hwang et al., 2002; Woods et al., 2001) . It is an intriguing possibility that MBK-2 regulates the activity and/or degradation of multiple proteins by facilitating phosphorylation by GSK-3 or additional kinases.
